您好，欢迎来到试剂仪器网！ [登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > Amuvatinib hydrochloride(MP470 hydrochloride)
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Amuvatinib hydrochloride(MP470 hydrochloride)
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Amuvatinib hydrochloride(MP470 hydrochloride)图片
CAS NO:1055986-67-8
包装与价格：
包装价格(元)
5mg电议
10mg电议
50mg电议
100mg电议

产品介绍
Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) 是一种口服生物可利用的多靶点酪氨酸激酶抑制剂，对突变 c-Kit、PDGFRα、Flt3、c-Met 和 c-Ret 具有强效活性。 Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) 也是一种 DNA 修复抑制剂，通过抑制 DNA 修复蛋白 RAD51，从而破坏 DNA 损伤修复。抗肿瘤活性。
Cas No.1055986-67-8
别名MP470 hydrochloride; HPK 56 hydrochloride
Canonical SMILESS=C(N1CCN(C2=C3OC4=CC=CC=C4C3=NC=N2)CC1)NCC5=CC=C6OCOC6=C5.[x].Cl
分子式C23H21N5O3S.xHCl
溶解度Soluble in DMSO
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Amuvatinib hydrochloride (MP470 hydrochloride) is a multi-targeted receptor tyrosine kinases inhibitor, which inhibits c-Kit (D816V), c-Kit (D816H), c-Kit (V560G), c-Kit (V654A), PDGFRα (D842V), and PDGFRα (V561D) with IC50s of 950 nM, 10 nM, 34 nM, 127 nM, 81 nM, and 40 nM, respectively[1]. Antineoplastic activity[2].

MP470, a novel receptor tyrosine kinase (RTK) inhibitor has shown growth inhibitory activity against a variety of cancer cell lines. MP470 is effective on LNCaP and PC-3 cells with an IC50 of ~4 μM and 8 μM, respectively. When Erlotinib (10 μM) is combined with varying doses of MP470, the IC50 of MP470 decreased to 2 μM on LNCaP cells[2]. Akt activity (as measured by phosphorylation on Ser473) is significantly reduced by 10 μM MP470 alone but is not reduced by Erlotinib or Imatinib Mesylate (IM). Moreover, MP470 plus Erlotinib completely abolished Akt phosphorylation in LNCaP cells with an unchanged total protein level of Akt[2].

Four LNCaP xenograft arms each with 12 mice are dosed intraperitoneally with DMSO (control) or Erlotinib 80 mg/kg or MP470 50 mg/kg or Erlotinib 80 mg/kg plus MP470 50 mg/kg daily for 2 weeks and then observed for a further 11 days. Individual therapy with MP470 or Erlotinib shows modest tumor growth inhibition (TGI), while MP470 plus Erlotinib has a marked effect on TGI (45-65%). However, due to the high doses of MP470 used, only five or one mouse remained alive in the combination arm at the end of treatment or at the end of the study, respectively. Therefore the MP470 dose is reduced to 10 mg/kg or 20 mg/kg for the combination treatment. TGI in the group receiving 10 mg/kg MP470+80 mg/kg Erlotinib is not significantly different from the control group. However, mice receiving 20 mg/kg MP470+80 mg/kg Erlotinib have a significant TGI compared to the control group (p=0.01)[2].

[1]. David J. Bearss, et al. Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same. US20080226747A1. [2]. Qi W, et al. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer. 2009 May 11;9:142.